İlhan-Mutlu, AyşegülTezcan, GülçinSchoppmann, Sebastian F.Preusser, MatthiasSpyridoula, KommataKaranikas, GeorgiosBirner, Peter2024-08-122024-08-122015-01-010735-7907https://doi.org/10.3109/07357907.2015.1024319https://www.tandfonline.com/doi/full/10.3109/07357907.2015.1024319https://hdl.handle.net/11452/43922We investigated whether microRNA-21 and microRNA-148a are predictive for neoadjuvant treatment in esophageal adenocarcinoma. Thirty-six patients with neoadjuvant therapy and surgical resection were included. FFPE tissue from biopsy and esophagectomy were analyzed using RT-qPCR. Results were correlated to histological tumor regression, histopathological variables, FDG-PET-CT and survival. MicroRNA-21 was significantly higher in esophagectomies than in corresponding biopsies (p = .027). No association of microRNA-21 or micro RNA-148a expression in tissue specimens with other clinical parameters was present. Although no influence of microRNA-21 and microRNA-148a on the response to neoadjuvant therapy was seen, upregulation of micro RNA-21 might represent an escape mechanism of tumor cells.eninfo:eu-repo/semantics/closedAccessPrognostic-significanceCancerInvasionProliferationTherapyEsophageal cancerAdenocarcinomamicroRNA-21microRNA-148aNeoadjuvant therapyFDG-PET-CTOncologyArticle00036130890000624625033610.3109/07357907.2015.1024319